Stay updated on Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial page.

Latest updates to the Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial page
- ChecktodayChange DetectedThe timeline for the modernization of the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025, with the version revision changing from v2.16.2 to v2.16.4.SummaryDifference2%
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check50 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check65 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed study information regarding the safety and clinical activity of nivolumab and relatlimab in treating MSS colorectal cancer, as well as the deletion of specific inclusion and exclusion criteria for participants. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference24%
- Check72 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 28, 2025.SummaryDifference0.7%
Stay in the know with updates to Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial page.